News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


YM Bio gets clearance to import nimotuzumab for clinical research into US (For Pontine Gliomas)

Posted on: 09/25/2006

Monday, 25th September 2006 09:06

YM Bio gets clearance to import nimotuzumab for clinical research into US

LONDON (AFX) - YM BioSciences Inc, the developer of oncology and acute care products, said it received clearance from the US Treasury Department's Office of Foreign Assets Control (OFAC) to import nimotuzumab into the US for the purpose of clinical trials in pediatric patients with pontine glioma.

Nimotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor.

YM said it will now file an Investigational New Drug (IND) application to the US Food & Drug Administration for permission to investigate nimotuzumab for the treatment of children with intrinsic diffuse pontine glioma, an inoperable malignant brain cancer that only affects children.

Nimotuzumab, which is currently approved in India, China, Argentina, and Columbia as well as Cuba, was recently licensed by YM to Daiichi Pharmaceutical Co for the Japanese market.

In Europe and Canada, the drug is in numerous clinical trials including non-small cell lung cancer, pediatric glioma and refractory

solid tumours. That latter study evaluated nimotuzumab as monotherapy and demonstrated significant clinical benefit in this highly refractory patient population, YM said.



Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557